Ascendis Pharma A/S
ASND
$164.65
-$4.19-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.98% | 117.21% | 171.64% | 337.71% | 443.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.98% | 117.21% | 171.64% | 337.71% | 443.39% |
| Cost of Revenue | -0.41% | 66.65% | 90.87% | 293.20% | 273.61% |
| Gross Profit | 43.26% | 129.68% | 192.51% | 346.20% | 497.70% |
| SG&A Expenses | 10.07% | 8.46% | 8.93% | 14.60% | 23.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.10% | -9.16% | -0.57% | 9.63% | 21.30% |
| Operating Income | 38.61% | 43.31% | 36.63% | 34.76% | 16.57% |
| Income Before Tax | 21.15% | 28.50% | 17.05% | 7.87% | 15.03% |
| Income Tax Expenses | -33.24% | 45.59% | 59.21% | 38.46% | 42.44% |
| Earnings from Continuing Operations | 21.33% | 27.68% | 16.30% | 7.35% | 14.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.33% | 27.68% | 16.30% | 7.35% | 14.51% |
| EBIT | 38.61% | 43.31% | 36.63% | 34.76% | 16.57% |
| EBITDA | 39.73% | 44.46% | 37.72% | 35.90% | 17.23% |
| EPS Basic | 22.97% | 28.91% | 17.37% | 8.25% | 14.81% |
| Normalized Basic EPS | 22.80% | 29.72% | 18.11% | 8.76% | 15.32% |
| EPS Diluted | 22.97% | 28.91% | 17.37% | 8.25% | 14.81% |
| Normalized Diluted EPS | 22.80% | 29.72% | 18.11% | 8.76% | 15.32% |
| Average Basic Shares Outstanding | 2.85% | 1.69% | 1.33% | 1.01% | 0.38% |
| Average Diluted Shares Outstanding | 2.85% | 1.69% | 1.33% | 1.01% | 0.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
